<SEC-DOCUMENT>0001104659-23-068336.txt : 20230606
<SEC-HEADER>0001104659-23-068336.hdr.sgml : 20230606
<ACCEPTANCE-DATETIME>20230606080324
ACCESSION NUMBER:		0001104659-23-068336
CONFORMED SUBMISSION TYPE:	4
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20230602
FILED AS OF DATE:		20230606
DATE AS OF CHANGE:		20230606

REPORTING-OWNER:	

	OWNER DATA:	
		COMPANY CONFORMED NAME:			Clauser Noah
		CENTRAL INDEX KEY:			0001796466

	FILING VALUES:
		FORM TYPE:		4
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37467
		FILM NUMBER:		23994916

	MAIL ADDRESS:	
		STREET 1:		100 HIGH STREET
		STREET 2:		28TH FLOOR
		CITY:			BOSTON
		STATE:			MA
		ZIP:			02110

ISSUER:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Astria Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001454789
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	BUSINESS ADDRESS:	
		STREET 1:		75 STATE STREET
		STREET 2:		SUITE 1400
		CITY:			BOSTON
		STATE:			MA
		ZIP:			02109
		BUSINESS PHONE:		617-349-1971

	MAIL ADDRESS:	
		STREET 1:		75 STATE STREET
		STREET 2:		SUITE 1400
		CITY:			BOSTON
		STATE:			MA
		ZIP:			02109

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CATABASIS PHARMACEUTICALS INC
		DATE OF NAME CHANGE:	20090127
</SEC-HEADER>
<DOCUMENT>
<TYPE>4
<SEQUENCE>1
<FILENAME>tm2317752-3_4seq1.xml
<DESCRIPTION>OWNERSHIP DOCUMENT
<TEXT>
<XML>
<?xml version="1.0"?>
<ownershipDocument>

    <schemaVersion>X0407</schemaVersion>

    <documentType>4</documentType>

    <periodOfReport>2023-06-02</periodOfReport>

    <notSubjectToSection16>0</notSubjectToSection16>

    <issuer>
        <issuerCik>0001454789</issuerCik>
        <issuerName>Astria Therapeutics, Inc.</issuerName>
        <issuerTradingSymbol>ATXS</issuerTradingSymbol>
    </issuer>

    <reportingOwner>
        <reportingOwnerId>
            <rptOwnerCik>0001796466</rptOwnerCik>
            <rptOwnerName>Clauser Noah</rptOwnerName>
        </reportingOwnerId>
        <reportingOwnerAddress>
            <rptOwnerStreet1>C/O ASTRIA THERAPEUTICS, INC.</rptOwnerStreet1>
            <rptOwnerStreet2>75 STATE STREET, SUITE 1400</rptOwnerStreet2>
            <rptOwnerCity>BOSTON</rptOwnerCity>
            <rptOwnerState>MA</rptOwnerState>
            <rptOwnerZipCode>02109</rptOwnerZipCode>
            <rptOwnerStateDescription></rptOwnerStateDescription>
        </reportingOwnerAddress>
        <reportingOwnerRelationship>
            <isDirector>0</isDirector>
            <isOfficer>1</isOfficer>
            <isTenPercentOwner>0</isTenPercentOwner>
            <isOther>0</isOther>
            <officerTitle>Chief Financial Officer</officerTitle>
            <otherText></otherText>
        </reportingOwnerRelationship>
    </reportingOwner>

    <aff10b5One>0</aff10b5One>

    <derivativeTable>
        <derivativeTransaction>
            <securityTitle>
                <value>Stock Option (Right to Buy)</value>
            </securityTitle>
            <conversionOrExercisePrice>
                <value>13.36</value>
            </conversionOrExercisePrice>
            <transactionDate>
                <value>2023-06-02</value>
                <footnoteId id="F1"/>
            </transactionDate>
            <deemedExecutionDate></deemedExecutionDate>
            <transactionCoding>
                <transactionFormType>4</transactionFormType>
                <transactionCode>A</transactionCode>
                <equitySwapInvolved>0</equitySwapInvolved>
            </transactionCoding>
            <transactionTimeliness></transactionTimeliness>
            <transactionAmounts>
                <transactionShares>
                    <value>100000</value>
                </transactionShares>
                <transactionPricePerShare>
                    <value>0</value>
                </transactionPricePerShare>
                <transactionAcquiredDisposedCode>
                    <value>A</value>
                </transactionAcquiredDisposedCode>
            </transactionAmounts>
            <exerciseDate>
                <footnoteId id="F2"/>
            </exerciseDate>
            <expirationDate>
                <value>2033-01-31</value>
            </expirationDate>
            <underlyingSecurity>
                <underlyingSecurityTitle>
                    <value>Common Stock</value>
                </underlyingSecurityTitle>
                <underlyingSecurityShares>
                    <value>100000</value>
                </underlyingSecurityShares>
            </underlyingSecurity>
            <postTransactionAmounts>
                <sharesOwnedFollowingTransaction>
                    <value>100000</value>
                </sharesOwnedFollowingTransaction>
            </postTransactionAmounts>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>D</value>
                </directOrIndirectOwnership>
            </ownershipNature>
        </derivativeTransaction>
    </derivativeTable>

    <footnotes>
        <footnote id="F1">This option was by granted effective as of February 1, 2023, subject to stockholder approval of an amendment to Astria Therapeutics, Inc.'s (the &quot;Company&quot;) Amended and Restated 2015 Stock Incentive Plan to increase the number of shares available for issuance thereunder by 4,300,000 (the &quot;Stock Plan Amendment Proposal&quot;). The Company's stockholders approved the Stock Plan Amendment Proposal on June 2, 2023.</footnote>
        <footnote id="F2">This option is subject to vesting over a four-year period, with 25% of the 100,000 shares underlying the option upon grant vesting on the first anniversary of February 1, 2023 and the remainder vesting over the ensuing three years in equal monthly installments.</footnote>
    </footnotes>

    <remarks>Exhibit 24 - Power of Attorney</remarks>

    <ownerSignature>
        <signatureName>/s/ Ben Harshbarger, as attorney-in-fact for Noah Clauser</signatureName>
        <signatureDate>2023-06-06</signatureDate>
    </ownerSignature>
</ownershipDocument>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-24
<SEQUENCE>2
<FILENAME>tm2317752d3_ex24.htm
<DESCRIPTION>EXHIBIT 24
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; margin: 0"><B>Exhibit 24</B></P>

<P STYLE="margin: 0; text-align: right">&nbsp;</P>

<P STYLE="margin: 0; text-align: right"><IMG SRC="tm2317752d3_ex24img001.jpg" ALT=""></P>

<P STYLE="margin: 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0; color: #494e53"><B>75 State Street, Suite&nbsp;1400, Boston
MA 02109&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>LIMITED POWER OF ATTORNEY</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FOR SECTION&nbsp;16 REPORTING OBLIGATIONS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Know all by these
presents, that the undersigned hereby makes, constitutes and appoints each of Jill C. Milne and Ben Harshbarger signing singly and each
acting individually, as the undersigned&rsquo;s true and lawful attorney-in-fact with full power and authority as hereinafter described
to:</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">execute
for and on behalf of the undersigned, in the undersigned&rsquo;s capacity as an officer of Catabasis Pharmaceuticals,&nbsp;Inc. (the &ldquo;Company&rdquo;),
Forms 3, 4, and 5 (including any amendments thereto) in accordance with Section&nbsp;16(a)&nbsp;of the Securities Exchange Act of 1934
and the rules&nbsp;thereunder (the &ldquo;Exchange Act&rdquo;);</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">do
and perform any and all acts for and on behalf of the undersigned which may be necessary or desirable to prepare, complete and execute
any such Form&nbsp;3, 4, or 5, prepare, complete and execute any amendment or amendments thereto, and timely deliver and file such form
with the United States Securities and Exchange Commission (the &ldquo;SEC&rdquo;) and any stock exchange or similar authority, including
without limitation the filing of a Form&nbsp;ID, Update Passphrase, or any other application materials to enable the undersigned to gain
or maintain access to the Electronic Data Gathering, Analysis and Retrieval system of the SEC;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">seek
or obtain, as the undersigned&rsquo;s representative and on the undersigned&rsquo;s behalf, information regarding transactions in the
Company&rsquo;s securities from any third party, including brokers, employee benefit plan administrators and trustees, and the undersigned
hereby authorizes any such person to release any such information to such attorney-in-fact and approves and ratifies any such release
of information; and</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">take
any other action of any type whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of benefit
to, in the best interest of, or legally required by, the undersigned, it being understood that the documents executed by such attorney-in-fact
on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as such
attorney-in-fact may approve in such attorney-in-fact&rsquo;s discretion.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The undersigned
hereby grants to each such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite,
necessary, or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as
the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming
all that such attorney-in-fact, or such attorney-in-fact&rsquo;s substitute or substitutes, shall lawfully do or cause to be done by virtue
of this power of attorney and the rights and powers herein granted. The undersigned acknowledges that the foregoing attorneys-in-fact,
in serving in such capacity at the request of the undersigned, are not assuming nor relieving, nor is the Company assuming nor relieving,
any of the undersigned&rsquo;s responsibilities to comply with Section&nbsp;16 of the Exchange Act. The undersigned acknowledges that
neither the Company nor the foregoing attorneys-in-fact assume (i)&nbsp;any liability for the undersigned&rsquo;s responsibility to comply
with the requirement of the Exchange Act, (ii)&nbsp;any liability of the undersigned for any failure to comply with such requirements,
or (iii)&nbsp;any obligation or liability of the undersigned for profit disgorgement under Section&nbsp;16(b)&nbsp;of the Exchange Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This Power of Attorney
shall remain in full force and effect until the undersigned is no longer required to file Forms 3, 4, and 5 with respect to the undersigned&rsquo;s
holdings of and transactions in securities issued by the Company, unless earlier revoked by the undersigned in a signed writing delivered
to the foregoing attorneys-in-fact.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">IN WITNESS WHEREOF, the undersigned
has caused this Power of Attorney to be executed as of June 3, 2023.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sign:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 45%">/s/ <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Noah Clauser</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Noah Clauser</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>tm2317752d3_ex24img001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2317752d3_ex24img001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  Y *H# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^JMYJ$%A
M%YEPX4<G\!U/T'<]!3KNX^SV[R!"[ <*.Y_I]:X^;6)M0N!+]M:VM24A2*.,
MEV\S[K=.21D@?PCYCSQ5QC<WHT74UZ%Z]\7V@61 E_'\H:%HK?<\_KM4@_+T
M^8@ YX-8">,[X1J\%C/)(5)+S3PG(7[Q$8<8Q]>*K1>'-5UB[NX@%,$<K*)[
MV(^6IS_RSAS\YZ?.Y.<5OS>"+V7:8/$=U:J(U3RX(46/(4!CM]R"2/>NR$:,
M=)/\_P!#T)PPU+2]W\_T&7VO7EK<6UY%<SQVMW")L7,*R0Q'C*DQ_.AZ98[E
M!-;^A:T=7M&D>W\F1#@[6WQR#LT;CAE/Y^H%<1JG@?6[A[2"YNHKQ(F"PWUL
M/LT]H">NT?*Z^O\ %Z&N>L=0GT?48;'5 T\,A6XC*AX_MBALB5!P4F&.1QO
MP><%NI8.G6I?NY)R7;MK_6OKMJ<<J<&O==SV\'-%<SX7\7V_B&XOK0Q""\M'
MYCW;@\1Y213CD$8/XUTU>54ISI2Y)JS.5JSLPHHHK,04444 %%%4=7UG3]"T
M]K[4[I+:V4@&1\]3T&!R30!>HK+T#Q#IWB;3?[0TN5I;4NR!V0KDCKP>:U*
M"BD->/>%?B'XGUCXHSZ)>V:)9;I$: 1X:W" D,6ZG)V@YXY&,4 >Q44@Z4M
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(84@ZFEH _]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
